Andere talen Longeveron Inc.

Aandelen

LGVN

US54303L2034

Vertraagde tijd Nasdaq Andere beurzen 18:07:34 01-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,73 ^USD	+1,17%		+0,58%	-87,28%

08/04	Top premarket stijgers	MT
20/03	Longeveron gaat 1 voor 10 omgekeerde aandelensplitsing doorvoeren	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Longeveron Files Prospectus for Secondary Offering	30/04
Longeveron to Present at the Planet MicroCap Showcase	25/04
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering	18/04
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds	17/04
Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation	16/04
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)	15/04
Top Premarket Gainers	15/04
Longeveron Announces Closing of $5.2 Million Public Offering	11/04
Longeveron Announces Pricing of $5.25 Million Public Offering	08/04
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals	08/04
Top Premarket Gainers	08/04
Longeveron to Effect 1-for-10 Reverse Stock Split	20/03
Longeveron Announces 1-for-10 Reverse Stock Split	19/03
Longeveron Reports Year-End 2023 Results and Provides Corporate Update	27/02
Longeveron Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024	21/02
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™	29/01
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind Its Lead Investigation Product Lomecel-B	29/01
Longeveron Closes $2.4 Million Offering	22/12
Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	21/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Longeveron Inc.

Aandelen

LGVN

US54303L2034

Andere talen

Filters